GemPharmatech (SH:688046) Zheng Quan Zhi Xing·2025-06-25 16:59Core Viewpoint - The company has announced the cancellation of a special settlement account for fundraising financial products and the establishment of new accounts for cash management of excess and idle fundraising funds, ensuring compliance with relevant regulations and maintaining the safety and efficiency of fund utilization [2][3][5]. Group 1: Cancellation of Special Settlement Account - The company has completed the cancellation of the special settlement account for fundraising financial products at Huatai Securities, as all purchased financial products have matured and been redeemed [3]. - The account details for cancellation include the account number 666810028046 at Huatai Securities [3]. Group 2: Establishment of New Accounts - The company has opened new special settlement accounts for fundraising financial products at Shenwan Hongyuan Securities and CITIC Securities [3]. - These accounts will be used exclusively for cash management of excess and idle fundraising funds and will not be used for non-fundraising purposes [3]. Group 3: Cash Management and Risk Control - The company plans to use part of the excess and idle fundraising funds for cash management, ensuring that it does not affect the normal operation of fundraising investment projects [5]. - The company will adhere to relevant regulations and implement strict risk control measures, including monitoring product performance and taking timely actions if adverse factors are identified [4]. Group 4: Impact on the Company - The cash management of excess and idle funds is expected to improve the efficiency of fund utilization and generate certain financial returns for the company and its shareholders [5]. - The company assures that this action will not change the intended use of fundraising funds or affect the normal development of its main business [5].